Since May, there have been more than 700 global cases of monkeypox identified in countries outside West and Central Africa where the virus is endemic.
Though no deaths have been reported so far, the highly unusual outbreak has health officials around the world scrambling to understand how the virus is spreading and to ensure there are enough vaccines and treatments on hand should it pick up speed.
“We should expect to see more cases and more tests in the coming days,” Raj Panjabi, senior director for Global Health Security and Biodefense in the White House, said during the press briefing.
The World Health Organization said last week that the outbreak presented a “moderate” risk to global public health. On Thursday, Maria Van Kerkhove, who leads emerging diseases and zoonoses teams at the WHO, said the organization suspects that person-to-person transmission has been happening for weeks in Europe.
The CDC maintains the risk to Americans is “low,” but is holding regular briefings about the status of the outbreak. Most cases in the U.S. have been among men who identify as gay, bisexual or men who have sex with men, but health officials caution that the disease can spread through close contact between any individuals.
The federal government has distributed 1,200 smallpox and monkeypox vaccines and 100 treatment courses to eight states to inoculate close contacts of monkeypox patients. Over 340 contacts of confirmed cases have been identified, with more than 20 considered to be at “high” risk and more than 120 considered to be at “intermediate” risk.
The first cases in the U.S. were confirmed in mid May in Massachusetts and New York, and cases have subsequently been confirmed in California, Colorado, Florida, Georgia, Illinois, Pennsylvania, Virginia and Washington.
Federal health officials are urging doctors to submit samples from suspected cases to the network of laboratories around the nation that can test for monkeypox or orthopox, a related virus.
The Strategic National Stockpile contains doses of two vaccines that can be used to prevent and treat monkeypox: a newer two-dose vaccine approved for monkeypox and smallpox called Jynneos, and an older vaccine approved for use against smallpox, but which can be used for monkeypox, called ACAM2000.
On Friday, Assistant Secretary for Preparedness and Response Dawn O’Connell declined to say how many doses of either were in the stockpile, citing national security. “We have enough vaccine on hand to manage the current outbreak,” she said.
O’Connell said the vaccines were positioned at SNS sites around the country, and that there were additional doses of the Jynneos vaccine in storage with the manufacturer, Bavarian Nordic.
Last month, the CDC said the SNS contained over 1,000 doses of Jyenneos and over 100 million doses of ACAM2000. The agency said on Friday that the numbers for Jynneos were no longer accurate, but declined to elaborate on whether there were now fewer or more doses available.
Daniel Payne contributed to this report.